Tompkins, AK, Cooke, DT, Backhus, L, DiMaio, JM, Pereira, SJ, Antonoff, MB , Merrill, WH, Erkmen, CP, Pereira, SJ, Backhus, LM, Bostock Rosenzweig, IC, Bowen, D, Cooke, DT, Erhunmwunsee, L, Freeman, KA, Godoy, L, Kozik, D, Kpodonu, J, Lagisetty, KH, Pelletier, GJ, Sihag, S, Wallace, AF, Wilder, F, Wood, DE, Arora, A, Boffa, DJ, Kaiser, LR, Macheers, SK, Martin, LW, Misselbeck, TS, Spurlock, DJ, Squiers, J, Reece, TB, Okusanya, O, Tong, BC, Gillaspie, EA, Fiedler, A, Kidane, B, Kim, MP, Krueger, A, Mitzman, B, Mokadam, NA, Pal, J, Vardas, P, Yang, SC, Dexter, E, Rove, J, Saddoughi, SA, Serna-Gallegos, D, Nelson, DB
The temptation to escalate the dose because nothing is happening yet is exactly the mistake the timeline section is designed to head off the mechanism is cumulative, not dose-chased
IGF-1 LR3 1 is a modified version of native IGF-1 that contains an arginine substitution at position 3 and a 13-amino-acid extension at the N-terminus
Forme liposomale associe de la phosphatidylcholine de lcithine de tournesol non OGM